JanOne Inc

JanOne, Inc. engages on the development of treatments for diseases that cause severe pain. It operates through the following segments: Biotechnology, Recycling, and Technology. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment consists of a turnkey appliance recycling program, which receives fees charged for recycling and replacement and additional services for utility energy efficiency programs. JanOne was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

JanOne, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

LAS VEGAS, March 15, 2024 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, today announced that on March 13, 2024 it received a notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market Inc. ("Nasdaq") indicating that the Company had regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the "Minimum Bid Price Requirement"). As previously announced, the Company received a notification letter from Nasdaq on September 11, 2023, indicating that the closing bid price per share had been below $1.00 for a period of 30 consecutive business days and that the Company did not meet the Minimum Bid Price Requirement.

JanOne Regains Compliance with Nasdaq's Listing Requirements

JanOne (NASDAQ: JAN ) stock is on the rise Thursday despite a lack of news from the clinical-stage biopharmaceutical company. There haven't been any news press releases of filings with the Securities and Exchange Commission (SEC) from the company that would cause today's rally.

Why Is JanOne (JAN) Stock Up 40% Today?

Chief Medical Officer Dr. Amol Soin will explain innovative approaches to pain management and JanOne's development of non-addicting treatments for pain LAS VEGAS , Sept. 21, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, will participate in investor sessions at the Dawson James Securities 8th Annual Investment Conference in Jupiter, Florida.

JanOne to Present at the Dawson James 8th Annual Investment Conference

Chief Medical Officer Dr. Amol Soin will discuss innovative approaches to pain management and JanOne's development of non-addicting treatments for pain LAS VEGAS , Aug. 31, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, will participate in investor sessions at the H.C. Wainwright 25 th  Annual Global Investment Conference in New York City.

JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference

The Broad Patent Coverage is a Major Milestone for the Commercial Success of Jan123 LAS VEGAS , Aug. 29, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the visionary biotech company dedicated to discovering non-addictive treatments for pain, as well as causes of pain, has earned a US patent for its innovative formulation of low-dose naltrexone, Jan123, for treating pain. The Broad Patent Coverage is a Major Milestone for the Commercial Success of Jan123  Jan123 is being developed to treat complex regional pain syndrome (CRPS), a rare and often life-altering condition characterized by severe pain and hypersensitivity to touch.

JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain

Abstract explained Jan101's statistically significant reduction in pain and improvement in nerve conduction velocity in prior Phase II study. LAS VEGAS , Aug. 25, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, has won a prestigious "Best Abstract" award for reporting that JanOne's treatment for diabetic neuropathy showed both effectiveness against pain and potential to improve nerve function.

JanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual Meeting

LAS VEGAS, Aug. 22, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN) (the "Company"), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 899,348 shares of the Company's common stock (or prefunded warrants in lieu thereof) at a purchase price of $0.8811 per share of common stock (or prefunded warrant) in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued unregistered warrants to purchase 899,348 shares of common stock at an exercise price of $0.7561 per share.

JanOne Technologies Announces Closing of Registered Direct Offering Priced At-The-Market under Nasdaq Rules

LAS VEGAS , Aug. 18, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN) (the "Company"), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 899,348 shares of the Company's common stock (or prefunded warrants in lieu thereof) at a purchase price of $0.8811 per share of common stock (or prefunded warrant) in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase 899,348 shares of common stock at an exercise price of $0.7561 per share.

JanOne Technologies Announces Registered Direct Offering Priced At-The-Market under Nasdaq Rules

JAN101 Showed Statistically Significant Reduction in Pain and Improvement in Nerve Conduction Velocity in Prior Phase II study. LAS VEGAS , Aug. 18, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, will present prior data on Jan101's randomized double blind placebo-controlled trial in diabetic neuropathy patients.

JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual Meeting

Patent filing marks another milestone in becoming a world leader in pain management LAS VEGAS , June 28, 2023 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a biopharmaceutical company that is developing multiple drugs to treat chronic diseases like Peripheral Artery Disease (PAD) and Complex Regional Pain Syndrome (CRPS), has just filed an international patent application for methods of using low dose naltrexone to treat chronic pain. Dr. Amol Soin, the chief medical officer and inventor mentioned, "This patent filing, should it issue, will bolster our plans to help treat patients suffering from complex regional pain syndrome across the globe, using our novel formulation and dosing strategy that we feel will be advantageous with our drug candidate, Jan123.

JanOne files international patent application for methods of using low dose naltrexone to treat chronic pain

JanOne (Nasdaq: JAN), the biopharmaceutical innovator specializing in non-addicting painkillers and new treatments for the causes of pain, has completed a successful pre-IND meeting with the FDA regarding Jan123. Jan123 is the company's unique oral delivery of low dose naltrexone formulated to treat complex regional pain syndrome, an orphan disease of severe, debilitating impact.

JanOne Completes Pre-IND Meeting with FDA on Jan123

LAS VEGAS , April 13, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), Dr. Amol Soin, Chief Medical Officer of JanOne, will be presenting at the Appalachian Region Spine and Pain Meeting in Sulfur Springs, West Virginia on Saturday, April 15 th on the topic of Innovation in Pain Medicine and will be discussing the drug development programs at JanOne. JanOne is a biotech company that is developing two different late-stage non-opioid drug candidates: JAN 101 is designed to treat peripheral artery disease that was also shown to improve pain in patients with diabetic neuropathy in a phase II study and JAN 123 which is low dose naltrexone to treat Complex Regional Pain Syndrome.

JanOne to Present Data On Its Two Non-Opioid Drug Candidates at The Appalachian Region Spine and Pain Meeting on Drug Development Programs to Treat Pain on April 15, 2023

LAS VEGAS , March 24, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced the closing of its previously announced registered direct offering of 361,000 shares of the Company's common stock at a purchase price of $1.17 per share of common stock priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

JanOne Technologies Announces Closing of Registered Direct Offering of Common Stock Priced At-The-Market

Bonfiglio is known for raising capital, building start-ups, and leading successful biotech companies as CEO and COO.      LAS VEGAS , March 23, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, announced the hiring of John N.

JanOne Welcomes John Bonfiglio -- Veteran Biotech Executive, Deal Maker and Strategist -- to Top Management Team

LAS VEGAS , March 23, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 361,000 shares of the Company's common stock at a purchase price of $1.17 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about March 24, 2023, subject to the satisfaction of customary closing conditions.

JanOne Technologies Announces Registered Direct Offering of Common Stock Priced At-The-Market

Sale reduces liabilities by $17.6 million and entails at least $24 Million in future payments  LAS VEGAS , March 22, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, announced that on March 9, 2023 they entered into a Stock Purchase Agreement with VM7, a Delaware corporation, under which VM7 agreed to acquire all of the outstanding equity interests of ARCA Recycling, Inc, Customer Connexx LLC and ARCA Canada Inc. Virland Johnson, who has served as ARCA Recycling's CFO and COO for several years is the principal of VM7. Sale reduces liabilities by $17.6 million and entails at least $24 Million in future payments.

JanOne Sells Legacy Business ARCA Recycling to Concentrate on Growing BioPharm Businesses

JAN 123's in vitro study on low dose naltrexone vies for the Society's "Best Research Abstract of the Year"   LAS VEGAS , Feb. 22, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, will present data on two of its investigational pharmaceutical compounds at the American Society of Interventional Pain Physicians (ASIPP) annual meeting in Washington DC in March, 2023. Dr. Amol Soin, Chief Medical Officer of JanOne, will present results from the Phase IIa trial of JAN 101, which treats patients with painful diabetic peripheral neuropathy.

JanOne to Present Important Trial Results at Annual Meeting of American Society of Interventional Pain Physicians

In meetings hosted by Nasdaq MarketSite , the company reviewed its drug development programs that fight the opioid crisis through pharmaceuticals that reduce pain without causing addiction. LAS VEGAS , Jan. 26, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), which develops treatments for underlying causes of severe pain and brings to market drugs that relieve pain without the risk of addiction, held meetings at New York's Nasdaq MarketSite to review strategic plans and to facilitate integration of recently-acquired Soin Therapeutics.

JanOne Charts Ambitious Strategic Course for Non-Addictive Pain Management

The acquisition of Soin provides JanOne with its second, late stage clinical stage asset LAS VEGAS , Jan. 10, 2023 /PRNewswire/ -- JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that it has completed the acquisition of Soin Therapeutics, LLC and its product, a patent-pending, novel formulation of low-dose naltrexone. This all stock transaction has a value of $13M, with up to an additional $17M depending on revenues generated by the product, for a total value of up to $30M.

JanOne Inc. Completes Acquisition of Soin Therapeutics, LLC

The acquisition of Soin will provide JanOne with its second clinical stage product LAS VEGAS , Sept. 16, 2022 /PRNewswire/ -- JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that it has executed a term sheet to acquire Soin Therapeutics LLC and its product, a patent-pending, novel formulation of low dose naltrexone.

JanOne Inc. Executes Term Sheet to Acquire Soin Therapeutics LLC

MINNEAPOLIS , July 5, 2022 /PRNewswire/ -- ARCA Recycling, Inc. (ARCA), a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), unveiled a new logo that aligns its visual identity with the innovative and environmentally responsible services it offers. While ARCA's core mission to deliver best-in-class energy efficiency and environmental protection programs remains unchanged, the company has expanded its customer base in recent years.

ARCA Recycling, a Subsidiary of JanOne Inc., Unveils New Logo and Website

Wejo Group Ltd

Bird Rides

Endo International

Tuniu Corp

Penny stocks to watch with news The post Penny Stocks To Watch: Why TOUR, JAN, ENDP, BRDS & WEJO Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Watch: Why TOUR, JAN, ENDP, BRDS & WEJO Stock Are Moving

Recent Developments at the University of Iowa have Resulted in an Improved Formulation of JAN101 LAS VEGAS , June 28, 2022 /PRNewswire/ -- JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that work has been completed by Dr. Maureen Donovan at the University of Iowa that will allow for an improved formulation of JAN101. JAN101 (formerly known as TV1001SR), is a potential treatment for peripheral artery disease (PAD), a vascular disease that affects more than 8.5 million people in the U.S. and more than 60 million people worldwide.

JanOne Inc. Announces an Improved Formulation of JAN101

MINNEAPOLIS , June 9, 2022 /PRNewswire/ -- ARCA Recycling, Inc., (ARCA), a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), will open three new recycling centers in June and July of this year to support growth in its recycling business and to help ARCA better serve its customers across North America. The new recycling facilities are located in Kent, Washington, Tulare, California and Hainesport, New Jersey.

ARCA Recycling, Inc., a Subsidiary of JanOne Inc., Opens Three New Recycling Centers in Washington, California and New Jersey

Accelerate Diagnostics

Transocean

Can these penny stocks make gains this month? The post Best Penny Stocks to Buy Now?

News for JanOne Inc Stock (JAN)